Clover Health Investments, Corp
3.6400-0.12 (-3.19%)
Oct 29, 4:00:02 PM EDT · NasdaqGS · CLOV · USD
Key Stats
Market Cap
1.87BP/E (TTM)
-Basic EPS (TTM)
-0.08Dividend Yield
0%Recent Filings
8-K
Clover addresses shareholder queries
Clover Health released written responses to shareholder questions on August 11, 2025, ahead of its Q2 earnings, with Executive Chairman Vivek Garipalli highlighting the company's PPO model's success in delivering broad physician access and strong outcomes through AI-driven Clover Assistant. This approach contrasts competitors' narrowing networks, fostering clinician trust and data feedback for financial viability. Clover positions itself as an AI leader in Medicare Advantage by embedding technology at the point of care. Forward-looking statements note risks like regulatory changes and execution challenges.
10-Q
Q2 FY2025 results
Clover Health's Q2 FY2025 results showed robust revenue growth, with premiums earned jumping 34.3% year-over-year to $469.8M, fueled by a 32% rise in average membership to 106,323, while total revenues climbed 34.1% to $477.6M. Yet net medical claims surged 52.2% to $378.0M, pushing the benefits expense ratio to 88.4% from 76.1% amid higher Part D costs from the Inflation Reduction Act and less favorable prior-year developments; this flipped operating income to a $10.6M loss from a $7.2M gain, yielding diluted EPS of -$0.02 on 509M shares. Cash and equivalents dipped to $188.6M, with operating cash use of $10.9M for the half-year, but liquidity holds at $389.3M including investments—no debt burdens or M&A noted. Non-GAAP Adjusted EBITDA came in at $17.1M, defined and reconciled in the filing. Regulatory pressures from CMS's planned RADV audit ramp-up pose a key risk to risk-adjustment revenues.
8-K
Clover Health Q2 growth surges
Clover Health reported Q2 2025 results with Medicare Advantage membership hitting 106,323, up 32% year-over-year, driving total revenues to $478 million, a 34% jump. Adjusted EBITDA came in at $17 million, while GAAP net loss narrowed to $11 million; Insurance BER rose to 88.4%. The company raised full-year membership guidance to 104,000-108,000 but flagged regulatory risks to Medicare policies. Momentum builds.
8-K
Annual meeting results announced
Clover Health Investments held its 2025 Annual Meeting on June 10, electing Dr. Anna U. Loengard and William G. Robinson, Jr. as Class I directors with strong support—over 976 million FOR votes each—while 162 million broker non-votes reflected routine abstentions. Stockholders overwhelmingly approved executive compensation for 2024 (99% FOR) and ratified Ernst & Young as auditors for 2025 (over 1.15 billion FOR). Directors serve until 2028. Votes affirm governance stability.
8-K
Clover's Q1 shareholder Q&A
Clover Health released a Q&A on May 14, 2025, addressing shareholder queries ahead of Q1 2025 earnings, highlighting Adjusted EBITDA profitability in 2024 and guidance for 2025, alongside a Star Rating jump to 4 for 2026 that boosts revenue via quality bonuses. This enables better member benefits and ~30% membership growth, while Counterpart Health's SaaS model scales nationally for chronic care management. Yet profitability hinges on AI adoption amid regulatory risks.
ALHC
Alignment Healthcare, Inc.
18.21+0.17
AUNA
Auna SA
5.92-0.19
CI
The Cigna Group
299.12-9.29
CNC
Centene Corporation
37.34+4.15
CTEV
Claritev Corporation
68.60-2.58
CVS
CVS Health Corporation
80.60-1.60
ELV
Elevance Health, Inc.
336.36-3.04
MOH
Molina Healthcare Inc
160.28-2.56
MRAI
Marpai, Inc.
1.38-0.08
PIII
P3 Health Partners Inc.
8.66-0.22